Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Efavirenz 600mg Clear all
Completed Phase 4 Interventional Results available

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

NCT00924898
View directory record Official record
Conditions
Acute HIV Infection, HIV Infections
Interventions
efavirenz, emtricitabine, and tenofovir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Results available

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072
View directory record Official record
Conditions
HIV Infection
Interventions
Placebo, Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 23, 2026, 8:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 23, 2026, 8:56 PM EDT
Not listed Phase 2Phase 3 Interventional

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

NCT01641016
View directory record Official record
Conditions
HIV
Interventions
efavirenz
Drug
Lead sponsor
PENTA Foundation
Network
Eligibility
8 Years to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

NCT00540449
View directory record Official record
Conditions
HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
Interventions
TMC278, Efavirenz
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT01472380
View directory record Official record
Conditions
Healthy
Interventions
efavirenz, fenofibric acid 105 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)

NCT01867996
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, EFZ 600 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

NCT00661960
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
raltegravir, efavirenz
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

NCT00005018
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Abacavir sulfate, Efavirenz, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Results available

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

NCT00442962
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

NCT01585038
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Efavirenz, Rilpivirine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

NCT00862823
View directory record Official record
Conditions
Healthy
Interventions
tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

NCT00697892
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
lopinavir/ritonavir, efavirenz, artemether/lumefantrine
Drug
Lead sponsor
Fran Aweeka
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

NCT00727597
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
Efavirenz 600mg, Boosted Lexiva
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

NCT00004852
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 8:56 PM EDT
Terminated Phase 2 Interventional Results available

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

NCT02415595
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-955176, EFV, TDF/FTC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

NCT00344760
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Efavirenz, lamivudine, and tenofovir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Antimalarial and Anti-HIV Medications

NCT00266058
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

NCT00543725
View directory record Official record
Conditions
HIV Infections, HIV-1
Interventions
TMC278, efavirenz
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Results available

Efavirenz (EFV) Intensification

NCT07193875
View directory record Official record
Conditions
HIV
Interventions
Efavirenz 600mg
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

NCT00004585
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

NCT00870363
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 23, 2026, 8:56 PM EDT